Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti‐TNF failure—getting closer to the truth. Authors' reply

Abstract

LINKED CONTENT This article is linked to Biemans et al and Liu et al papers. To view these articles, visit https://doi.org/10.1111/apt.15745 and https://doi.org/10.1111/apt.16009

Letter: propensity score—handle with care

“…The excellent study by Biemans et al 2 used the correct methodology. Although reasonable anxieties about the small sample size and the lack of reporting of standardised difference score—which is needed to demonstrate that the covariates’ distribution is balanced independently of the sample size 4 —were expressed by Liu et al, 5 they were able to correctly address this issue 6 . The cut‐off value of the standardised difference (typically set at SD ≤ 0.10 when the imbalance between groups is negligible) can be higher in small cohorts.…”